Slide 1: Q2 2022 Earnings and Business Update Call
Q2 2022 Earnings and Business Update Call Sanara MedTech Evidence Based Healing
Slide 2: Disclaimers
Disclaimers v This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements ot
Slide 3: Commentary on Q2 2022
Commentary on Q2 2022 + Financial Update + Highest sales quarter ($9.7 million) in the Company's history; first quarter in which the Company generated >$3 million in sales in every month in the quarter + Net loss of $3.3 million for Q2 2022 + Netloss compared to Q2 2021 impacted by increased SG&A (+
Slide 4: Surgical Products
Surgical Products Surgical Overview + 35 field sales managers CellerateRX Surgical sold in 590 hospitals/ASCs in the TTM s CellerateRX Surgical sold in hospitals/ASCs across 27 states) in the TTM CellerateRX Surgical approved to be sold in 1,580 hospitals/ASCs Total estimated available market in the
Slide 5: Scendia Biologics Acquisition Overview
ogics Acquisition Overview + Additional Product Portfolio + We believe Scendia products could be beneficial to physicians who already use Cellerate products + Primary focus on four key products (though other products are still offered): + AMPLIFY™ Verified Inductive Bone Matrix + ALLOCYTE™ Advanced
Slide 6: Precision Healing Merger
Precision Healing Merger Capabilities and Strategic Rationale + Key Features + The imager is intended to be integrated with Sanara’s proprietary EMR system and virtual consult capability, with the goal of giving the Company the ability to diagnose, treat, track, collect, and further analyze data on
Slide 7: Q2 2022 Financial Highlights
Q2 2022 Financial Highlights Overview + Revenue + For the three months ended June 30, 2022, we generated net revenues of $9.7 million compared to net revenues of $6.3 million for the three months ended June 30, 2021, representing a 54% increase from the prior year period. + For the six months ended
Slide 8: Questions
Questions . Sanara “ MedTech Evidence Based Healing